{"organizations": [], "uuid": "c3bc4717139509b385b2065a784056ea305a1f0e", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "uk.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://feeds.reuters.com/reuters/UKHealthNews/", "section_title": "Reuters: Health News", "url": "https://uk.reuters.com/article/us-insys-opioids/insys-sees-no-change-in-estimated-litigation-costs-idUKKCN1IG2U4", "country": "US", "domain_rank": 408, "title": "Insys sees no change in estimated litigation costs", "performance_score": 0, "site": "reuters.com", "participants_count": 0, "title_full": "", "spam_score": 0.0, "site_type": "news", "published": "2018-05-15T20:58:00.000+03:00", "replies_count": 0, "uuid": "c3bc4717139509b385b2065a784056ea305a1f0e"}, "author": "", "url": "https://uk.reuters.com/article/us-insys-opioids/insys-sees-no-change-in-estimated-litigation-costs-idUKKCN1IG2U4", "ord_in_thread": 0, "title": "Insys sees no change in estimated litigation costs", "locations": [], "entities": {"persons": [{"name": "insys", "sentiment": "none"}, {"name": "manas mishra", "sentiment": "none"}, {"name": "shounak dasgupta", "sentiment": "none"}], "locations": [{"name": "bengaluru", "sentiment": "none"}, {"name": "subsys", "sentiment": "none"}], "organizations": [{"name": "insys", "sentiment": "negative"}, {"name": "insys therapeutics inc", "sentiment": "none"}, {"name": "u.s. department of justice", "sentiment": "none"}, {"name": "reuters", "sentiment": "none"}, {"name": "doj", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "May 15, 2018 / 6:01 PM / Updated an hour ago Insys sees no change in estimated litigation costs Reuters Staff 1 Min Read\n(Reuters) - Insys Therapeutics Inc said on Tuesday that it believed a previously estimated $150 million would be sufficient to cover expenses from an ongoing litigation related to the company’s sales practises.\nThe news comes a day after the U.S. Department of Justice joined a whistleblower lawsuit alleging Insys paid kickbacks to doctors.\nThe company continues to have an ongoing dialogue with the DOJ regarding this investigation, Insys said on Tuesday.\n“This ongoing dialogue has not resulted in information that would cause the company to revise this estimate (of $150 million),” the company said.\nThe government’s involvement was disclosed in a filing made public on Monday. It adds firepower to the civil litigation as Insys tries to resolve a federal probe into its marketing of Subsys, a spray form of fentanyl. Reporting by Manas Mishra in Bengaluru; Editing by Shounak Dasgupta", "external_links": [], "published": "2018-05-15T20:58:00.000+03:00", "crawled": "2018-05-15T21:52:41.006+03:00", "highlightTitle": ""}